157 related articles for article (PubMed ID: 28142059)
1. Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study.
Ursu R; Carpentier A; Metellus P; Lubrano V; Laigle-Donadey F; Capelle L; Guyotat J; Langlois O; Bauchet L; Desseaux K; Tibi A; Chinot O; Lambert J; Carpentier AF
Eur J Cancer; 2017 Mar; 73():30-37. PubMed ID: 28142059
[TBL] [Abstract][Full Text] [Related]
2. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study.
Carpentier A; Metellus P; Ursu R; Zohar S; Lafitte F; Barrié M; Meng Y; Richard M; Parizot C; Laigle-Donadey F; Gorochov G; Psimaras D; Sanson M; Tibi A; Chinot O; Carpentier AF
Neuro Oncol; 2010 Apr; 12(4):401-8. PubMed ID: 20308317
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma.
Carpentier A; Laigle-Donadey F; Zohar S; Capelle L; Behin A; Tibi A; Martin-Duverneuil N; Sanson M; Lacomblez L; Taillibert S; Puybasset L; Van Effenterre R; Delattre JY; Carpentier AF
Neuro Oncol; 2006 Jan; 8(1):60-6. PubMed ID: 16443949
[TBL] [Abstract][Full Text] [Related]
4. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
5. Oligodeoxynucleotides containing unmethylated cytosine-guanine motifs are effective immunostimulants against pneumococcal meningitis in the immunocompetent and neutropenic host.
Ribes S; Zacke L; Nessler S; Saiepour N; Avendaño-Guzmán E; Ballüer M; Hanisch UK; Nau R
J Neuroinflammation; 2021 Feb; 18(1):39. PubMed ID: 33531028
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
9. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
Alizadeh D; Zhang L; Brown CE; Farrukh O; Jensen MC; Badie B
Clin Cancer Res; 2010 Jul; 16(13):3399-408. PubMed ID: 20570924
[TBL] [Abstract][Full Text] [Related]
10. TLR9 expression is associated with prognosis in patients with glioblastoma multiforme.
Leng L; Jiang T; Zhang Y
J Clin Neurosci; 2012 Jan; 19(1):75-80. PubMed ID: 22169598
[TBL] [Abstract][Full Text] [Related]
11. CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study.
Otsuka T; Nishida S; Shibahara T; Temizoz B; Hamaguchi M; Shiroyama T; Kimura K; Miyake K; Hirata H; Mizuno Y; Yagita M; Manabe Y; Kuroda E; Takeda Y; Kida H; Ishii KJ; Kumanogoh A
BMC Cancer; 2022 Jul; 22(1):744. PubMed ID: 35799134
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study.
Ursu R; Thomas L; Psimaras D; Chinot O; Le Rhun E; Ricard D; Charissoux M; Cuzzubbo S; Sejalon F; Quillien V; Hoang-Xuan K; Ducray F; Portal JJ; Tibi A; Mandonnet E; Levy-Piedbois C; Vicaut E; Carpentier AF
Eur J Cancer; 2019 Mar; 109():129-136. PubMed ID: 30716716
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial.
Ursu R; Taillibert S; Banissi C; Vicaut E; Bailon O; Le Rhun E; Guillamo JS; Psimaras D; Tibi A; Sacko A; Marantidou A; Belin C; Carpentier AF
Cancer Sci; 2015 Sep; 106(9):1212-8. PubMed ID: 26094710
[TBL] [Abstract][Full Text] [Related]
14. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
15. Repolarization of glioblastoma macrophage cells using non-agonistic Dectin-1 ligand encapsulating TLR-9 agonist: plausible role in regenerative medicine against brain tumor.
Tiwari RK; Singh S; Gupta CL; Pandey P; Singh VK; Sayyed U; Shekh R; Bajpai P
Int J Neurosci; 2021 Jun; 131(6):591-598. PubMed ID: 32250189
[TBL] [Abstract][Full Text] [Related]
16. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
[TBL] [Abstract][Full Text] [Related]
18. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
19. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
[TBL] [Abstract][Full Text] [Related]
20. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Hainsworth JD; Ervin T; Friedman E; Priego V; Murphy PB; Clark BL; Lamar RE
Cancer; 2010 Aug; 116(15):3663-9. PubMed ID: 20564147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
